Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
NEW YORK, April 04, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 15th Annual Needham Healthcare Conference in New York. The presentation is scheduled for Tuesday, April 12, 2016 at 4:20 p.m. EDT.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
Contact: Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006
